The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients: An Italian Cost-Effectiveness Analysis.

Ippazio Cosimo Antonazzo Paolo Angelo CortesiGerardo Miceli SopoGiampiero Mazzaglia PierFranco ConteLorenzo Giovanni Mantovani

Published in: Cancers (2023)

This study estimated the appropriate price for tucatinib according to different WTP in order to help healthcare decision makers to better understand the treatment value.

Keyphrases

healthcare
squamous cell carcinoma
small cell lung cancer
decision making
health insurance